AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

November 15, 2020

Video

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!

Recent Videos

Victor Gonzalez, MD, speaks about his Clinical Trials at the Summit presentation, focusing on retinitis pigmentosa therapy MCO-010 (Nanoscope Therapeutics)

Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his research in OCS-01 drops for diabetic macular edema during ARVO

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Newsletter